Synapse - Works

Results (5608)

Molecular correlates differentiate response to atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Rini, B. I.; Huseni, M.; Atkins, M. B.; McDermott, D. F.; Powles, T. B.; Escudier, B.; Banchereau, R.; Liu, L. F.; Leng, N.; Fan, J.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

Meeting Abstract

Motzer, R. J.; Penkov, K.; Haanen, J. B. A. G.; Rini, B. I.; Albiges, L.; Campbell, M. T.; Kollmannsberger, C. K.; Negrier, S.; Uemura, M.; Lee, J. L.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors

Meeting Abstract

Garon, E. B.; Wong, D. J.; Schneider, J. G.; Aljumaily, R.; Korn, W. M.; Patel, M. R.; Autio, K. A.; Papadopoulos, K. P.; Naing, A.; Gabrail, N.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors

Meeting Abstract

Tannir, N. M.; Naing, A.; Papadopoulos, K. P.; Wong, D. J.; Korn, W. M.; Aljumaily, R.; Autio, K. A.; Pant, S.; Bauer, T. M.; Drakaki, A.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Meeting Abstract

Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D.; Choueiri, T. K.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Sunitinib tolerance following an initial exposure period: Results of longitudinal PRO data from S-TRAC study

Meeting Abstract

George, D. J.; Figlin, R.; Motzer, R. J.; Paty, J.; Lechuga Frean, M. J.; Zanotti, G.; Bhattacharyya, H.; Ramaswamy, K.; Deannuntis, L.; Ravaud, A.
Annals of Oncology (2018)

Fulltext@MSK | Save

A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914)

Meeting Abstract

Bex, A.; Grünwald, V.; Russo, P.; Tomita, Y.; Berghorn, E.; McHenry, M. B.; Motzer, R. J.
Annals of Oncology (2018)

Fulltext@MSK | Save

Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression

Meeting Abstract

Rosenberg, J.; Necchi, A.; Sweis, R. F.; Nakajima, K.; Lu, C.; Nogai, H.
Annals of Oncology (2018)

Fulltext@MSK | Save

Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Chowdhury, S.; McDermott, R.; Piulats, J. M.; Shapiro, J. D.; Mejlholm, I.; Morris, D.; Ostler, P.; Hussain, A.; Dumbadze, I.; Goldfischer, E. R.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B)

Meeting Abstract

Ryan, C. J.; Dutta, S.; Kelly, W.; Morris, M. J.; Taplin, M. E.; Halabi, S.
Annals of Oncology (2018)

Fulltext@MSK | Save